19
Participants
Start Date
October 21, 2019
Primary Completion Date
October 26, 2022
Study Completion Date
October 26, 2022
TAK-755
Participants will receive TAK-755 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.
Placebo
Participants will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.
Johns Hopkins University School Of Medicine, Baltimore
VCU Health - Research Parent, Richmond
Duke University Medical Center, Durham
East Carolina University, Greenville
Levine Cancer Institute, Charlotte
Medical University of South Carolina (MUSC), Charleston
University of Alabama at Birmingham, Birmingham
Ohio State University Medical Center, Columbus
Ochsner Health System, New Orleans
Arkansas Children's Hospital, Little Rock
University of Colorado Sickle Cell Treatment and Research Center, Aurora
Sickle Cell Center, Denver
University of Illinois, Chicago
University of Tennessee -- Memphis, Memphis
Lead Sponsor
Takeda Development Center Americas, Inc.
INDUSTRY
Shire
INDUSTRY